Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel in AR-Expressing Metastatic Breast Cancer
NCT01990209Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2014
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orteronel in breast cancer, sponsored by SCRI Development Innovations. Started Mar 2014; status: completed.
02
Drugs
orteronel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01990209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01990209.